智通财经获悉，继周二收涨近156%之后，周三美股盘前，Biora Therapeutics(BIOR.US)延续涨势。截至发稿，该股周三美股盘前涨50%，报8.1美元。消息面上，Biora Therapeutics在本周早些时候收到了美国食品药品监督管理局(FDA)对其针对溃疡性结肠炎的新药PGN-600项目临床开发计划的反馈和其他计划更新的支持。据悉，在202...
SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) --Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced it will report financial results and provide a corporate update for the third quarter ended September 30, 2024. Company management will host...
30, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it submitted an updated Investigational New Drug (IND) application for BT-600 to the U.S. Food and Drug Administrati...
Biora’s NaviCap targeted oral therapeutics platformutilizes a novel approach that could improve patient outcomes by enabling delivery of therapeutics directly to the site of disease, increasing therapeutic levels in...
our ability to innovate in the field of therapeutics, our ability to make future FDA filings and initiate and execute clinical trials on expected timelines or at all, our ability to obtain and main...
our ability to innovate in the field of therapeutics, our ability to make future FDA filings and initiate and execute clinical trials on expected timelines or at all, our ability to obtain and maintain regulatory approval or clearance of our products on expected timelines or at all, our plans ...
our ability to innovate in the field of therapeutics, our ability to make future FDA filings and initiate and execute clinical trials on expected timelines or at all, our ability to obtain and maintain regulatory approval or clearance of our products on expected timelines or at all, our plans ...